The role of Alternative Lengthening of Telomeres in human cancer by Henson, Jeremy D
  
The role of 
Alternative Lengthening of Telomeres 
in human cancer 
 
 
Jeremy D. Henson 
 
 
A thesis submitted to the University of Sydney 
in fulfilment of the requirements for the 
degree of Doctor of Philosophy 
 
 
The Children’s Medical Research Institute 
Faculty of Medicine 
The University of Sydney 
 
 
June, 2006 
  i 
  
Statement of Originality 
 
The contents of this thesis have not been presented for the award of a degree or 
diploma at this or any other university. The data presented are the original work of the 
author except where specifically indicated in the text. 
 
 
 
 
Jeremy D. Henson 
 
  ii 
Acknowledgements 
 
First and foremost I would like to thank my supervisor, Roger Reddel, for his support, 
and guidance. Roger is one of the most impressive people I have been associated with 
and has been an excellent role model. Roger’s persistent censoring of my scientific 
talks has probably been beneficial to both our careers. I would also like to thank my 
associate supervisor, Tracy Bryan. I have the highest respect for her expert guidance 
and wisdom. 
 
I am grateful to Peter Rowe and the Children’s Medical Research Institute for giving 
me the opportunity and support to complete my PhD in an environment that fosters 
science. I am also grateful to the NHMRC for their scholarship support. 
 
I thank all the people who have contributed in many ways during this work, including 
the following people. Especially, Axel Neumann, Sara Cole, Alessandra Muntoni, 
Elizabeth Collins, Paul Wang, Sharon Cunningham and all members of the Cancer 
research Group and the CMRI who have shared their scientific expertise with me and 
made this an enjoyable place to work. Tony Henwood who provided advice on 
tumour preparation, Jennifer Peat and Katrina Williams who provided advice on 
statistical analysis, and John Melki and Mark Hughes who provided advice on 
Microarray analysis.  
 
Thank you to Daniel Catchpoole, Lyra Pearson, Aileen Baillie, Sue Camara, Vicky 
Hakin-Smith, Thomas Carroll, David Levy, Suzanne Jackson, the Westmead 
  iii 
Children’s Hospital Tumour Bank and members of the Royds laboratory for tumour 
samples and data without which this work would not be possible.  
 
I am grateful to Nicola Royle, Nadia Zaffaroni, Curt Harris and Wei Qin Jiang for 
giving me the opportunity to collaborate with their interesting projects. 
 
And finally I am eternally grateful to my parents for their endless support and 
encouragement. 
  iv 
Publications 
 
 
1. Henson,J.D., Neumann,A.A., Yeager,T.R., and Reddel,R.R. (2002). 
Alternative lengthening of telomeres in mammalian cells. Oncogene 21, 598-
610. 
 
2. Henson,J.D., Hannay,J.A., McCarthy,S.W., Royds,J.A., Yeager,T.R., 
Robinson,R.A., Wharton,S.B., Jellinek,D.A., Arbuckle,S.M., Yoo,J., 
Robinson,B.G., Learoyd,D.L., Stalley,P.D., Bonar,S.F., Yu,D., Pollock,R.E., 
and Reddel,R.R. (2005). A robust assay for alternative lengthening of 
telomeres (ALT) in tumors demonstrates the significance of ALT in sarcomas 
and astrocytomas. Clin. Cancer Res. 11, 217-225. 
 
3. Jeyapalan,J.N., Varley,H., Foxon,J.L., Pollock,R.E., Jeffreys,A.J., 
Henson,J.D., Reddel,R.R., and Royle,N.J. (2005). Activation of the ALT 
pathway for telomere maintenance can affect other sequences in the human 
genome. Hum. Mol. Genet. 14, 1785-1794. 
 
4. Jiang,W.Q., Zhong,Z.H., Henson,J.D., Neumann,A.A., Chang,A.C.M., and 
Reddel,R.R. (2005). Suppression of alternative lengthening of telomeres by 
Sp100-mediated sequestration of MRE11/RAD50/NBS1 complex. Mol. Cell. 
Biol. 25, 2708-2721. 
 
5. Costa,A., Daidone,M.G., Daprai,L., Villa,R., Cantù,S. Pilotti,S., Mariani,L., 
Gronchi,A., Henson,J.D., Reddel,R.R. and Zaffaroni,N. Presence and Clinical 
Relevance of Telomere Maintenance Mechanisms in Liposarcoma. Cancer 
Research (Manuscript submitted, 2006) 
 
6. Jiang,W.Q., Zhong,Z.H., Henson,J.D. and Reddel,R.R. (2005). Screen of 
candidate genes required for ALT by RNA interference and methionine 
restriction. Oncogene (Manuscript submitted 2006) 
 
7. Bowman,E.D., Mechanic,L., Henson,J.D.,  Reddel,R.R., Welsh,J., Khan,M.,  
Hewitt,S.,  Dennis,P. and Harris.C.C.  AKT phosphorylation and telomere 
lengthening in lung cancer prognosis (Manuscript in preparation). 
  v 
 
Presentations 
 
1. Henson,J.D., Yeager,T.R., Robinson,R.A., Yoo,J., Robinson,B.G., 
Learoyd,D.L., Jellinek,D.A., Wharton,S.B., Royds,J.A., Eeles,R. and 
Reddel,R.R. Investigating Alternative Lengthening of Telomeres (ALT) in 
human tumors by detection of ALT-Associated PML Bodies. Lorne Cancer 
Conference, 2002. (Winner of Poster Prize) 
 
2. Henson,J.D., Yeager,T.R., Robinson,R.A., Yoo,J., Robinson,B.G., 
Learoyd,D.L., Jellinek,D.A., Wharton,S.B., Royds,J.A. and Reddel,R.R. 
Investigating Alternative Lengthening of Telomeres (ALT) in human tumors 
by detection of ALT-Associated PML Bodies. Australian Society for Medical 
Research, XIth NSW Scientific Meeting, 2002.  
 
3. Henson,J.D., Yeager,T.R., Arbuckle,S.M., Robinson,R.A., Yoo,J., 
Jellinek,D.A., Wharton,S.B., Royds,J.A., McCarthy,S.W., Eeles,R. and 
Reddel,R.R. Investigating Alternative Lengthening of Telomeres (ALT) in 
human tumors by detection of ALT-Associated PML Bodies. Australian 
Telomere Workshop I, 2002. 
 
4. Henson,J.D., Yeager,T.R., McCarthy,S.W., Pollock,R.E., Arbuckle,S.M., 
Robinson,R.A., Yoo,J., Robinson,B.G., Learoyd,D.L., Jellinek,D.A., 
Wharton,S.B., Royds,J.A., Eeles,R. and Reddel,R.R. Investigating Alternative 
Lengthening of Telomeres (ALT) in human tumors by detection of ALT-
Associated PML Bodies (APBs). Lorne Cancer Conference, 2003. 
 
5. Henson,J.D., Hannay,J.A., McCarthy,S.W., Royds,J.A., Yeager,T.R., 
Robinson,R.A., Wharton,S.B., Jellinek,D.A., Arbuckle,S.M., Yoo,J., 
Robinson,B.G., Learoyd,D.L., Stalley,P.D., Bonar,S.F., Yu,D., Pollock,R.E., 
and Reddel,R.R. A robust assay for alternative lengthening of telomeres 
(ALT) in tumors demonstrates the significance of ALT in sarcomas and 
astrocytomas. Australian Telomere Workshop II, 2004. 
 
6. Henson,J.D., Hannay,J.A., Royds,J.A., McCarthy,S.W., Yeager,T.R., 
Nuemann,A.A., Robinson,R.A., Wharton,S.B., Jellinek,D.A., Arbuckle,S.M., 
Yoo,J., Harris,C.C., Robinson,B.G., Learoyd,D.L., Stalley,P.D., Bonar,S.F., 
Yu,D., Pollock,R.E., and Reddel,R.R. Development of an assay for  
Alternative Lengthening of Telomeres (ALT). Children’s Hospital Westmead, 
Grand Rounds, 2004. 
 
7. Henson,J.D., Yeager,T.R., McCarthy,S.W., Pollock,R.E., Arbuckle,S.M., 
Bonar,S.F., Robinson,R.A., Yoo,J., Jellinek,D.A., Wharton,S.B., Royds,J.A., 
Robinson,B.G., Learoyd,D.L., Eeles,R. and Reddel,R.R. A robust assay for 
alternative lengthening of telomeres (ALT) in tumors demonstrates the 
significance of ALT in sarcomas and astrocytomas. Australian Health and 
Medical Research Congress, 2004. 
 
  vi 
8. Henson,J.D., Hannay,J.A., McCarthy,S.W., Royds,J.A., Yeager,T.R., 
Robinson,R.A., Wharton,S.B., Jellinek,D.A., Arbuckle,S.M., Yoo,J., 
Robinson,B.G., Learoyd,D.L., Stalley,P.D., Bonar,S.F., Yu,D., Pollock,R.E., 
and Reddel,R.R. A robust assay for alternative lengthening of telomeres 
(ALT) in tumors demonstrates the significance of ALT in sarcomas and 
astrocytomas. Children's Cancer Institute Australia, Seminar, 2005. 
 
9. Henson,J.D., Hannay,J.A., McCarthy,S.W., Royds,J.A., Yeager,T.R., 
Robinson,R.A., Wharton,S.B., Jellinek,D.A., Arbuckle,S.M., Yoo,J., 
Robinson,B.G., Learoyd,D.L., Stalley,P.D., Bonar,S.F., Yu,D., Pollock,R.E., 
and Reddel,R.R. A robust assay for alternative lengthening of telomeres 
(ALT) in tumors demonstrates the significance of ALT in sarcomas and 
astrocytomas. Australian Institute for Medical Scientists, National Scientific 
Meeting, 2005. 
 
 
  vii 
Summary 
 
Activation of a telomere maintenance mechanism is a vital step in the development of 
most cancers and provides a target for the selective killing of cancer cells. Cancers 
can use either telomerase or Alternative Lengthening of Telomeres (ALT) to maintain 
their telomeres and inhibition of either telomere maintenance mechanism can cause 
cancer cells to undergo senescence or apoptosis. Although telomerase inhibitors are 
undergoing clinical trials, on commencing this study very little was known about the 
role of ALT in cancer, what proteins were involved in its mechanism and regulation 
and how it could be targeted clinically. The primary aim of this thesis was to develop 
an assay for ALT suitable for examining archived tumour specimens and to begin 
using it to examine the prevalence and clinical significance of ALT in cancer. This 
assay and gene expression analysis was also used to identify genes that are involved 
in or associated with the activation of the ALT mechanism, to contribute towards the 
overall goal of an ALT cancer therapy. 
 
The ALT mechanism involves recombination mediated replication and ALT cells 
have a marked increase in a range of recombinational events specifically at their 
telomeres. Presumably, as a consequence of this the telomere lengths of ALT cells are 
very heterogeneous and on average long. This can be detected by terminal restriction 
fragment (TRF) Southern analysis, which has been used previously as the definitive 
test for ALT activity. However, TRF analysis requires intact genomic DNA and is 
unsuitable for tumour specimens which are commonly archived by paraffin 
embedding. Another hallmark of ALT is ALT-associated PML bodies (APBs) which 
are the subset of PML bodies that contain telomeric DNA. Work done in this study to 
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consolidate APBs as a hallmark of ALT, combined with published data, showed 29/31 
ALT[+], 3/31 telomerase[+] and 0/10 mortal cell lines/strains are APB[+]. The three 
APB[+]/telomerase[+] cell lines identified here had an order of magnitude lower 
frequency of APB[+] nuclei than the ALT[+] cell lines. APBs may be functionally 
linked to the ALT mechanism and contain the recombination proteins that are thought 
to be involved in the ALT mechanism. This study, in collaboration with Dr W-Q 
Jiang, strengthened this functional link by demonstrating that loss of ALT activity (as 
determined by TRF analysis) coincided with the disruption of APBs.  
 
The detection of APBs was developed into a robust assay for ALT in archived tumour 
specimens using a technique of combined immunofluorescence and telomere 
fluorescence in situ hybridisation. It was demonstrated that the APB assay concurred 
exactly with the standard assay for ALT (TRF analysis) in 60 tumours for which TRF 
analysis gave unequivocal results. The APB assay may be a more appropriate 
technique in the case of tumour specimen heterogeneity, which may explain why the 
APB assay was able to give definitive results when TRF analysis was equivocal. We 
demonstrated that intratumoral heterogeneity for ALT does exist and this could 
explain why about 3% of tumours in this study were APB[+] but with more than a 
ten-fold reduction in the frequency of APB[+] nuclei. This study also made the novel 
discovery of single stranded C-rich telomeric DNA inside APBs which potentially 
could be used to make the APB assay more suitable for routine pathology laboratory 
use. 
 
The APB assay was used to show that ALT is a significant concern for oncology. 
ALT was utilised in approximately one quarter of glioblastoma multiforme (GBM), 
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one third of soft tissue sarcomas (STS) including three quarters of malignant fibrous 
histiocytomas (MFH), half of osteosarcomas and one tenth of non-small cell lung 
carcinomas (NSCLC). Furthermore, the patients with these ALT[+] tumours had poor 
survival; median survivals were 2 years for ALT[+] GBM, 4 years for ALT[+] STS 
including 3.5 years for ALT[+] MFH and 5 years for ALT[+] osteosarcoma. ALT[+] 
STS and osteosarcomas were also just as aggressive as their ALT[-] counterparts in 
terms of grade and patient outcome. ALT status was not found to be associated with 
response to chemotherapy in osteosarcomas or survival in STS. ALT was however, 
less prevalent in metastatic STS. 
 
 
The APB assay was a prognostic indicator for GBM and was correlated with three 
fold increased median survival in GBM (although this survival was still poor). ALT 
was more common in lower grade astrocytomas (88% ALT[+]) than GBM (24% 
ALT[+]) and ALT[+] GBM had an identical median age at diagnosis to that reported 
for secondary GBM. It is discussed that these data indicate that ALT was indirectly 
associated with secondary GBM and is possibly an early event in its progression from 
lower grade astrocytoma. This is relevant because secondary GBM have distinct 
genetic alterations that may facilitate activation of the ALT mechanism. 
 
Putative repressors of ALT could explain why this study found that ALT varied 
among the different STS subtypes. ALT was common in MFH (77%), 
leiomyosarcoma (62%) and liposarcoma (33%) but rare in rhabdomyosarcoma (6%) 
and synovial sarcoma (9%). ALT was not found in colorectal carcinoma (0/31) or 
thyroid papillary carcinoma (0/17) which have a high prevalence of telomerase 
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activity and a reduced need for a telomere maintenance mechanism (low cell 
turnover), respectively. 
 
A yeast model of ALT predicts that one of the five human RecQ helicases may be 
required for ALT. Using the APB assay to test for the presence of ALT in tumours 
from patients with known mutations in either WRN or RECQL4 it was demonstrated 
that neither of these RecQ helicases is essential for ALT. Although p53 and mismatch 
repair (MMR) proteins have been suggested to be possible repressors of ALT, there 
was no apparent increase in the frequency of ALT in tumours from patients with a 
germline mutation in p53 codon 273 or in colorectal carcinomas that had 
microsatellite instability and thus MMR deficiency. Also contrary to being a repressor 
of ALT but consistent with its ability to interact with a protein involved in the ALT 
mechanism, the MMR protein MLH1, was demonstrated to be present in the APBs of 
an ALT[+] cell line. 
 
To further test for genes that may be involved in the ALT mechanism or associated 
with its activation, RNA microarray was used to compare the gene expression of 12 
ALT[+]  with 12 matched telomerase[+] cell lines; 240 genes were identified that 
were significantly differentially expressed (p<0.005) between the ALT[+] and 
telomerase[+] cell lines. Only DRG2 and SFNX4 were significantly differentially 
expressed after adjusting for the estimated false positive rate. Overall, DRG2, MGMT 
and SATB1 were identified as most likely to be relevant to the ALT[+] tumours and 
Western analysis indicated that DRG2 and MGMT levels were down-regulated after 
activation of ALT and up-regulated after activation of telomerase, whereas SATB1 
protein levels appeared to be up-regulated after immortalisation but to a higher degree 
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with activation of ALT compared to telomerase.  Since lack of MGMT is known to be 
a determinant of temozolomide sensitivity in GBM, the possibility that ALT and the 
APB assay could be used to predict temozolomide sensitivity is discussed. The 
microarray data was consistent with MGMT expression being suppressed by EGF (p 
< 0.05), indicating that caution may be needed with combining EGFR inhibitors with 
temozolomide in ALT cancers. One ALT[+] cell line which did not express MGMT 
had TTAA sequence in its telomeres. This could possibly have resulted from 
mutations due to lack of MGMT expression and a possible role for MGMT in the 
ALT mechanism is discussed. 
 
Further analysis of the microarray data identified two groups of co-regulated genes (p 
< 5x10-5): CEBPA, TACC2, SFXN4, HNRPK and MGMT, and SIGIRR, LEF1, 
NSBP1 and SATB1. Two thirds of differentially expressed genes were down-
regulated in ALT. Chromosomes 10 and 15 had a bias towards genes with lower 
expression in ALT while chromosomes 1, 4, 14 and X had a bias towards genes with 
higher expression levels in ALT. 
 
This work has developed a robust assay for ALT in tumour specimens which was then 
used to show the significance of ALT in sarcomas, astrocytomas and NSCLC. It has 
also identified genes that could possibly be molecular targets for the treatment of 
ALT[+] cancers.  
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